Trijardy Xr

Active Ingredient(s): Empagliflozin + Linagliptin + Metformin Hydrochloride
FDA Approved: * January 27, 2020
Pharm Company: * BOEHRINGER INGELHEIM
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Trijardy Xr Overview

Empagliflozin/linagliptin/metformin, sold under the brand name Trijardy XR, is a drug combination used for the treatment of type 2 diabetes.[2] It is a combination of empagliflozin, linagliptin, and metformin. Empagliflozin/linagliptin/metformin was approved for use in the United States in January 2020.[3][4] Contents 1 Adverse effects 2 History 3 References 4 External links Adverse effects To lessen the risk of developing ketoacidosis (a...

Read more Trijardy Xr Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Empagliflozin/linagliptin/metformin

Recent Trijardy Xr Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Empagliflozin + Linagliptin + Metformin Hydrochloride
  • Tablet, Extended Release: 10mg + 5mg + 1gm, 12.5mg + 2.5mg + 1gm, 25mg + 5mg + 1gm, 5mg + 2.5mg + 1gm
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Trijardy Xr: (4 results)

Sorted by National Drug Code
  • 0597-0380 Trijardy XR Oral Tablet, Extended Release by Boehringer Ingelheim Pharmaceuticals, Inc.
  • 0597-0385 Trijardy XR Oral Tablet, Extended Release by Boehringer Ingelheim Pharmaceuticals, Inc.
  • 0597-0390 Trijardy XR Oral Tablet, Extended Release by Boehringer Ingelheim Pharmaceuticals, Inc.
  • 0597-0395 Trijardy XR Oral Tablet, Extended Release by Boehringer Ingelheim Pharmaceuticals, Inc.

Drugs with one or more similar ingredients: (33 results)